Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Parkinson's Disease | Research

Neutrophil to lymphocyte ratio in parkinson’s disease: a systematic review and meta-analysis

Authors: Samaneh Hosseini, Nasim Shafiabadi, Monireh Khanzadeh, Arshin Ghaedi, Raziyeh Ghorbanzadeh, Amir Azarhomayoun, Aida Bazrgar, Jalil Pezeshki, Hanieh Bazrafshan, Shokoufeh Khanzadeh

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

The goal of this research was to explore the role of Neutrophil to lymphocyte ratio (NLR) in Parkinson’s disease (PD).

Methods

From inception to 4 June 2023, PubMed, Web of Science, and ProQuest were searched for papers comparing NLR in PD to healthy individuals. Standardized mean difference (SMD) with a confidence interval (CI) of 95% were calculated.

Results

A random-effect model revealed that PD patients had elevated NLR values compared to healthy individuals (SMD = 0.81, 95% CI = 0.47 to 1.14, P < 0.001). The results of subgroup analysis were as follows: (1) study design: We observed that patients with PD had higher levels of NLR than healthy controls in either retrospective (SMD = 1.12, 95% CI = 0.58 to 1.66, P < 0.001) or prospective (SMD = 0.43, 95% CI = 0.18 to 0.68, P = 0.001) studies. (2) Ethnicity: We noticed that individuals with PD had higher levels of NLR than healthy controls, whether they were East Asian (SMD = 0.93, 95% CI = 0.22 to 1.63, P = 0.010) or Caucasian (SMD = 0.75, 95% CI = 0.40 to 1.10, P < 0.001).The pooled sensitivity of NLR in the prediction of PD was 0.67 (95% CI = 0.61–0.73), and the pooled specificity was 0.66 (95% CI, 0.61–0.70).

Conclusions

Increased levels of NLR is highly related with the presence of PD. Further research is needed to determine the potential clinical benefits of this simple and low-cost biomarker in the PD diagnosis.
Appendix
Available only for authorised users
Literature
1.
Leigh RM. Parkinson’s disease. Rumi Michael Leigh; 2019.
2.
Tan E-K, Chao Y-X, West A, Chan L-L, Poewe W, Jankovic J. Parkinson disease and the immune system—associations, mechanisms and therapeutics. Nat Reviews Neurol. 2020;16(6):303–18.
3.
Zesiewicz TA. Parkinson disease. CONTINUUM: Lifelong Learning in Neurology. 2019;25(4):896–918.PubMed
4.
Berg D, Borghammer P, Fereshtehnejad S-M, Heinzel S, Horsager J, Schaeffer E, et al. Prodromal Parkinson disease subtypes—key to understanding heterogeneity. Nat Reviews Neurol. 2021;17(6):349–61.
5.
Balestrino R, Schapira A. Parkinson disease. Eur J Neurol. 2020;27(1):27–42.PubMed
6.
Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36(1):1–12.PubMed
7.
Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Reviews Neurol. 2019;15(4):234–42.
8.
Bloem BR, Okun MS, Klein C. Parkinson’s disease. The Lancet. 2021;397(10291):2284–303.
9.
Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al. Parkinson disease-associated cognitive impairment. Nat Reviews Disease Primers. 2021;7(1):1–21.
10.
Pajares M, Rojo I, Manda A, Boscá G, Cuadrado L. Inflammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells. 2020;9(7):1687.PubMedPubMedCentral
11.
Han X, Sun S, Sun Y, Song Q, Zhu J, Song N, et al. Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. Autophagy. 2019;15(11):1860–81.PubMedPubMedCentral
12.
Borsche M, König IR, Delcambre S, Petrucci S, Balck A, Brüggemann N, et al. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. Brain. 2020;143(10):3041–51.PubMedPubMedCentral
13.
Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. npj Parkinson’s Disease. 2021;7(1):1–13.
14.
Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G. Neurodegeneration and Inflammation—An interesting interplay in Parkinson’s disease. Int J Mol Sci. 2020;21(22):8421.PubMedPubMedCentral
15.
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–60.PubMed
16.
Rolli-Derkinderen M, Leclair-Visonneau L, Bourreille A, Coron E, Neunlist M, Derkinderen P. Is Parkinson’s disease a chronic low-grade inflammatory bowel disease? J Neurol. 2020;267(8):2207–13.PubMed
17.
Joshi N, Singh S. Updates on immunity and inflammation in Parkinson disease pathology. J Neurosci Res. 2018;96(3):379–90.PubMed
18.
McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord. 2004;10:3–S7.
19.
Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022:1–17.
20.
Chen L, Mo M, Li G, Cen L, Wei L, Xiao Y, et al. The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Translational Neurodegeneration. 2016;5(1):1–6.
21.
Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol. 2011;68(1):22–30.PubMed
22.
23.
Miller DB, O’Callaghan JP. Biomarkers of Parkinson’s disease: present and future. Metabolism. 2015;64(3):40–S6.
24.
Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson’s disease: advances and strategies. Parkinsonism Relat Disord. 2016;22:106–S10.
25.
Akıl E, Bulut A, Kaplan İ, Özdemir HH, Arslan D, Aluçlu MU. The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson’s disease. Neurol Sciences: Official J Italian Neurol Soc Italian Soc Clin Neurophysiol. 2015;36(3):423–8.
26.
Ataç Uçar C, Gökçe Çokal B, Ünal Artık HA, İnan LE, Yoldaş TK. Comparison of neutrophil-lymphocyte ratio (NLR) in Parkinson’s disease subtypes. Neurol Sciences: Official J Italian Neurol Soc Italian Soc Clin Neurophysiol. 2017;38(2):287–93.
27.
Contaldi E, Magistrelli L, Cosentino M, Marino F, Comi C. Lymphocyte Count and Neutrophil-to-lymphocyte ratio are Associated with mild cognitive impairment in Parkinson’s Disease: a Single-Center Longitudinal Study. J Clin Med. 2022;11(19):5543.PubMedPubMedCentral
28.
Jiang L, Zhong Z, Huang J, Bian H, Huang W. Monocytohigh-density lipoprotein ratio has a high predictive value for the diagnosis of multiple system atrophy and the differentiation from Parkinson’s disease. Front Aging Neurosci. 2022;14.
29.
Jiang S, Wang Y, Gao H, Luo Q, Wang D, Li Y et al. Cell ratio differences in peripheral blood between early-and late-onset Parkinson’s disease: a case-control study. BioMed Research International. 2019;2019.
30.
Jin H, Gu H-y, Mao C-j, Chen J, Liu C. -f. Association of inflammatory factors and aging in Parkinson’s disease. Neurosci Lett. 2020;736:135259.PubMed
31.
Kara SP, Altunan B, Unal A. Investigation of the peripheral inflammation (neutrophil–lymphocyte ratio) in two neurodegenerative diseases of the central nervous system. Neurol Sci. 2022;43(3):1799–807.PubMed
32.
Kenangil G, Ari B, Kaya F, Demir M, Domac F. Red cell distribution width levels in Parkinson’s disease patients. Acta Neurol Belgica. 2020;120(5):1147–50.
33.
Liu Z, Fan Q, Wu S, Wan Y, Lei Y. Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson’s disease. Lipids Health Dis. 2021;20(1):1–12.
34.
Madetko N, Migda B, Alster P, Turski P, Koziorowski D, Friedman A. Platelet-to-lymphocyte ratio and neutrophil-tolymphocyte ratio may reflect differences in PD and MSA-P neuroinflammation patterns. Neurol Neurochir Pol. 2022;56(2):148–55.PubMed
35.
Muñoz-Delgado L, Macías‐García D, Jesús S, Martín‐Rodríguez JF, Labrador‐Espinosa M, Jiménez‐Jaraba MV, et al. Peripheral Immune Profile and Neutrophil‐to‐lymphocyte ratio in Parkinson’s Disease. Mov Disord. 2021;36(10):2426–30.PubMed
36.
Paul KC, Kusters C, Furlong M, Zhang K, Yu Y, Folle AD, et al. Immune system disruptions implicated in whole blood epigenome-wide association study of depression among Parkinson’s disease patients. Brain Behav Immunity-Health. 2022;26:100530.
37.
Pekel, NB, Yildiz 1 D, Siğirli 2 D, Yabaci 2 A, Seferoğlu1 M, Güneş1 A. Parkinson’s Disease: Is it Actually an inflammatory disorder? Turkish J Geriatr. 2018;21(4):483–9.
38.
Sanjari Moghaddam H, Ghazi Sherbaf F, Mojtahed Zadeh M, Ashraf-Ganjouei A, Aarabi MH. Association between Peripheral inflammation and DATSCAN Data of the Striatal nuclei in different motor subtypes of Parkinson Disease. Front Neurol. 2018;9:234.PubMedPubMedCentral
39.
Solmaz V, Genç EP, Aksoy D, Çevik B, Kurt SG, Benli İ. Parkinson hastalarında nötrofil/lenfosit oranları, C reaktif protein ve sedimantasyon hızlarının değerlendirilmesi. Cukurova Med J (Çukurova Üniversitesi Tıp Fakültesi Dergisi).43(2):1-.
40.
Wang L-x, Liu C, Shao Y-q, Jin H, Mao C-j, Chen J. Peripheral blood inflammatory cytokines are Associated with Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s Disease. Neurosci Lett. 2022:136692.
41.
Wang Y, Gao H, Jiang S, Luo Q, Han X, Xiong Y, et al. Principal component analysis of routine blood test results with Parkinson’s disease: a case-control study. Exp Gerontol. 2021;144:111188.PubMed
42.
Xing N, Dong Z, Wu Q, Kan P, Han Y, Cheng X et al. Identification and validation of key molecules associated with humoral immune modulation in Parkinson’s disease based on bioinformatics. Front Immunol. 2022;13.
43.
Yazar HO, Yazar T. Serum inflammation biomarkers are associated with stages of Parkinson’s disease. 2019.
44.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.PubMed
45.
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000.
46.
Goldet G, Howick J. Understanding GRADE: an introduction. J Evidence-Based Med. 2013;6(1):50–4.
47.
Muñoz-Delgado L, Macías-García D, Periñán MT, Jesús S, Adarmes-Gómez AD, Bonilla Toribio M, et al. Peripheral inflammatory immune response differs among sporadic and familial Parkinson’s disease. npj Parkinson’s Disease. 2023;9(1):12.PubMedPubMedCentral
48.
Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:210–S2.
49.
Hirsch EC, Standaert DG. Ten unsolved questions about neuroinflammation in Parkinson’s disease. Mov Disord. 2021;36(1):16–24.PubMed
50.
Tiwari PC, Pal R. The potential role of neuroinflammation and transcription factors in Parkinson disease. Dialogues in clinical neuroscience. 2022.
51.
De Virgilio A, Greco A, Fabbrini G, Inghilleri M, Rizzo MI, Gallo A, et al. Parkinson’s disease: autoimmunity and neuroinflammation. Autoimmun rev. 2016;15(10):1005–11.PubMed
52.
Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Translational Neurodegeneration. 2015;4(1):1–9.
53.
Song S-Y, Zhao X-X, Rajah G, Hua C, Kang R-j, Han Y-p, et al. Clinical significance of baseline neutrophil-to-lymphocyte ratio in patients with ischemic stroke or hemorrhagic stroke: an updated meta-analysis. Front Neurol. 2019;10:1032.PubMedPubMedCentral
54.
Yu S, Arima H, Bertmar C, Clarke S, Herkes G, Krause M. Neutrophil to lymphocyte ratio and early clinical outcomes in patients with acute ischemic stroke. J Neurol Sci. 2018;387:115–8.PubMed
55.
Muñoz-Delgado L, Labrador‐Espinosa M, Macías‐García D, Jesús S, Benitez Zamora B, Fernández‐Rodríguez P et al. Peripheral inflammation is Associated with Dopaminergic Degeneration in Parkinson’s Disease. Mov Disord. 2023.
56.
Song L, Zhang S, Li H, Hansson O, Sonestedt E, Borné Y. Comparison of risk factors for Parkinson’s disease, coronary events and ischemic stroke. npj Parkinson’s Disease. 2022;8(1):107.PubMedPubMedCentral
57.
Gelders G, Baekelandt V, Van der Perren A. Linking neuroinflammation and neurodegeneration in Parkinson’s disease. Journal of immunology research. 2018;2018.
58.
More SV, Kumar H, Kim IS, Song S-Y, Choi D-K. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease. Mediators of inflammation. 2013;2013.
59.
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2018;4:575–90.
60.
Lyon MS, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C, Inflammation. Immunity, and amyotrophic lateral sclerosis: I. etiology and pathology. Muscle Nerve. 2019;59(1):10–22.PubMed
61.
Lu C-H, Allen K, Oei F, Leoni E, Kuhle J, Tree T et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurology-Neuroimmunology Neuroinflammation. 2016;3(4).
62.
Vivekanantham S, Shah S, Dewji R, Dewji A, Khatri C, Ologunde R. Neuroinflammation in Parkinson’s disease: role in neurodegeneration and tissue repair. Int J Neurosci. 2015;125(10):717–25.PubMed
63.
Troncoso-Escudero P, Parra A, Nassif M, Vidal RL. Outside in: unraveling the role of Neuroinflammation in the progression of Parkinson’s Disease. Front Neurol. 2018;9:860.PubMedPubMedCentral
64.
Boyd RJ, Avramopoulos D, Jantzie LL, McCallion AS. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J Neuroinflamm. 2022;19(1):1–20.
Metadata
Title
Neutrophil to lymphocyte ratio in parkinson’s disease: a systematic review and meta-analysis
Authors
Samaneh Hosseini
Nasim Shafiabadi
Monireh Khanzadeh
Arshin Ghaedi
Raziyeh Ghorbanzadeh
Amir Azarhomayoun
Aida Bazrgar
Jalil Pezeshki
Hanieh Bazrafshan
Shokoufeh Khanzadeh
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03380-7

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue

Research

Functional connectivity of the language area in migraine: a preliminary classification model

Research

Association between physical activity and health literacy in patients with Parkinson’s disease: an online web survey

Research

Normobaric oxygen may attenuate the headache in patients with patent foramen povale and migraine

Study Protocol

Multidomain interventions for non-pharmacological enhancement (MINE) program in Chinese older adults with mild cognitive impairment: a multicenter randomized controlled trial protocol

Case Report

Anterior horn damage in brachial multisegmental amyotrophy with superficial siderosis and dural tear: an autopsy case report

Research

Transcranial sonography with clinical and demographic characteristics to predict cognitive impairment in PD: a longitudinal study